H ypertension is the most prevalent cardiovascular risk factor worldwide.
H ypertension is the most prevalent cardiovascular risk factor worldwide. 1 Exercise blood pressure (BP) and heart rate (HR) predict future hypertension in normotensives 2 and are associated with standard cardiovascular risk factors 3 and cardiovascular morbidity and mortality in patients with hypertension. [4] [5] [6] Renal sympathetic nerve activity is involved in the development and maintenance of arterial hypertension by interacting with renin release, renal blood flow, and tubular sodium reabsorption. 7 In addition, the sympathetic nervous system contributes to the physiological response to physical stress, leading to augmented HR, cardiac output, and BP. 8 Catheter-based renal denervation (RDN) has been proven to be safe and effective in reducing systolic BP (SBP) and diastolic BP (DBP) in patients with resistant hypertension. 9, 10 Data on the effect of RDN on physiological adaptation during physical exercise in patients with resistant hypertension are scarce. Ukena et al 11 reported an increase in maximum workload 3 months after RDN, assessed by cardiopulmonary exercise testing in 37 patients included in the Symplicity HTN-2 trial. However, cardiopulmonary exercise testing is a relatively complex and time-consuming procedure that is not widely available. In contrast, cycle exercise testing is a routinely performed, easily applicable method, broadly used in clinical practice. 12 Therefore, we investigated herein the effect of RDN on HR and BP at rest, during exercise, and at recovery in patients with resistant hypertension by cycle exercise testing after a follow-up (FU) period of 6 and 12 months.
Methods

Studied Patients
The study included 60 patients aged ≥18 years with resistant hypertension according to the international European Society of Hypertension guidelines (office SBP >140/90 mm Hg despite the use of ≥3 antihypertensive agents of different classes, including a diuretic
Hypertension
April 2014
at the maximum or highest tolerated dose). 13 The inclusion and exclusion criteria were otherwise similar to the Symplicity HTN-2 trial (NCT01888315). 9 The study was approved by the local ethics committees in accordance with the Declaration of Helsinki. Fifty patients underwent bilateral RDN, and 10 patients were assigned to the control group. Only patients with stable antihypertensive drug regimen were included in the study, and patients with known secondary causes of hypertension were excluded. Patients and physicians were instructed not to change antihypertensive medication during the study period, except when medically required.
Renal Sympathetic Denervation Procedure
The RDN procedure was performed via femoral access with a special radiofrequency catheter (Symplicity Catheter System, Ardian/ Medtronic Inc, CA). A detailed description of the procedure has been published elsewhere. 10 All RDN procedures were performed between February 2010 and October 2011. At the 6-month FU, patients were classified on the basis of their office BP to a responder group (SBP reduction ≥10 mm Hg) and a nonresponder group (SBP reduction <10 mm Hg). Office BP measurements were performed in a sitting position, and triplicate measurements were averaged in accordance with the guidelines. 13 Office HR was measured based on ECG.
Exercise Stress Test
The exercise stress test was performed at baseline and at 6-and 12-month FU after patients had taken their medication. Contraindication for exercise testing was defined according to American College of Cardiology/American Heart Association guidelines. 12 Patients performed bicycle exercises in a 90° position sitting on the ergometer (Sana Bike 250F; Ergosana GmbH, Bitz, Germany) under the supervision of a physician blinded to the RDN status. Resting BP was measured after sitting on the bicycle for ≥10 minutes. The procedure started with a workload of 75 W and increased continuously by 25 W every 3 minutes until the individual break-off threshold and was then followed by a recovery period of 5 minutes. HR and cardiac rhythm were constantly monitored with 12-lead ECG during the procedure. BP was measured every 60 seconds during the procedure, directly after break-off (recovery at 0 minutes), and during the recovery episode (1, 3, and 5 minutes after break-off) by an experienced physician using a manual sphygmomanometer. The test was terminated by the supervising physicians because of reasons defined in the guidelines 12 or if the patient was unable to continue. As expected, exercise time and workload were not similar among the patients because of differences in exercise capacity. With increasing workload, the number of patients reaching different levels of workload declined. To reduce the bias and for better comparability, the results (SBP, DBP, and HR) from the exercise stress tests are presented as a percentage of the individual maximum value. %SBPmax, %DBPmax, and %HRmax are calculated as percentage of maximum measured systolic, diastolic, and HR value, respectively, during the exercise stress test individually for every patient. Chronotropic index (CI) for bicycle-based exercise stress tests was calculated using the equation from Keteyian 
Results
Baseline patient characteristics in the treatment and control group were well matched ( Table 1) . Despite an intake of Response to treatment after 6 months was found in 43 (86%) patients. Five patients of the RDN group did not show up for the exercise test at the 6-month FU. Table 2 summarizes the %SBPmax values of the exercise test. In the intervention group, a significant reduction of %SBPmax ( Figure S1A -S1D in the online-only Data Supplement) from baseline to 6-month FU at rest, 75 W, 100 W, 150 W, recovery at 0 minutes, recovery after 1 minute, recovery after 3 minutes, and recovery after 5 minutes was observed. Twelve months after RDN, a significant decreased %SBPmax from baseline at 75 W, 100 W, 150 W, recovery at 0 minutes, recovery after 1 minute, recovery after 3 minutes, and recovery after 5 minutes was documented. Interestingly, no significant difference was observed on the absolute and relative extent of SBP reduction at different stages of the examination (Figure 1) . The results of the %DBPmax (Table 3 ) indicated for the RDN group a significant reduction from the baseline to the 6-month FU at rest, 75 W, 100 W, recovery after 3 minutes and from the baseline to the 12-month FU at rest, 75 W, 100 W, recovery after 1 minute, recovery after 3 minutes, and recovery after 5 minutes, respectively. There were no significant reductions at 125 W, 150 W, recovery at 0 minutes, recovery after 1 minute, and recovery after 5 minutes at the 6-month FU and also for 125 W, 150 W, and recovery at 0 minutes at the 12-month FU. SBP and DBP remained unchanged in the control group. The absolute BP values are depicted in the online-only Data Supplement (Tables  S1 and S2 ; Figure S1E -S1I).
Mean Exercise Time and Mean Workload
Mean exercise time (Figure 2A ) and mean workload ( Figure  2B ) in the RDN group increased significantly by 1.41±0.04 minutes (P<0.001) and 7±1 W (P<0.001) at 6-month FU and by 2.01±0.06 minutes (P=0.008) and 8±2 W (P=0.007) at 12-month FU.
Mean SBP at 100 W
A workload of ≥100 W at baseline and 6-month FU was achieved in 34 (57%) patients. Mean SBP at 100 W after 6 months ( Figure 3) 
Heart Rate and Chronotropic Index
Office HR was reduced by 3±1 to 64±1 bpm (P=0.054) 6 months after RDN. Figure S2 illustrates the decrease of HR in %HRmax during exercise stress test from baseline to 6-and 12-month FU, respectively. A significant reduction was observed at rest, 75 W, 100 W, 125 W, recovery after 1 minute, recovery after 3 minutes, and recovery after 5 minutes from baseline to 6-month FU, as well as 75 W, 100 W, 125 W, 150 W, and recovery after 1 minute from baseline to 12-month FU. During exercise stress test, CI remained unchanged after RDN at each visit (Figure 4 ). There were no significant changes in HR and CI in the control group.
Influence of Antihypertensive Medication or Physical Constitution
Antihypertensive drug regimen was reduced after 6 months in 4 patients in the RDN group because of the development of symptoms and confirmed low BP (SBP<120 mm Hg) and increased in 3 patients, 2 nonresponders in the RDN group and 1 patient in the control group, who continued to have BP above target after 6 months (Table 4) . Furthermore, no significant change in physical constitution assessed by the body mass index was observed during the FU period.
Discussion
Our study shows that RDN reduced SBP, DBP, and HR at rest, exercise, and recovery and increased mean workload and exercise time during exercise stress test without negatively influencing CI after 6 and 12 months in patients with resistant hypertension.
Exercise stress tests are reproducible methods for assessing the autonomic response to physical exercise. 15 Age, sex, body weight, cardiorespiratory fitness, and cardioactive drugs affect the BP response to exercise. 16 Dynamic exercise tolerance depends on a rise in cardiac output and a reduction in peripheral 17 Consequently, SBP increases in response to an increased stroke volume and systolic contractile force with increasing workload. 17 Thus, there is evidence indicating that an extensive rise in SBP during exercise is particularly associated with an exercise stimulation of the sympathetic nerves linked to enhanced risk of left ventricular hypertrophy, 18 myocardial infarction, 19 cerebrovascular stroke, 20 and cardiovascular death. 4, 21 SBP elevation during the postexercise (recovery) period is associated with stroke 20 and myocardial infarction. 22 DBP remains stable or decreases slightly during exercise as a result of vasodilatation and decrease in total peripheral resistance. 17 Similarly, DBP during exercise is associated with cardiovascular events. 4, 5 The present study shows that 6 and 12 months after RDN, SBP and DBP decreased at rest during all stages of exercise and during recovery.
The absolute difference in BP change after RDN was not significantly different between the levels of exercise. Clinically relevant benefits for the patients might be highest at mild-to-moderate levels of activity (75-100 W), 23 corresponding to the patients' daily life activity. 6 Importantly, a significant association of BP with cardiovascular death at this workload has been reported. 5, 6, 23 The observed BP profiles indicate an improved physiological BP adaptation without hypotension or inadequate BP rise during exercise. Our findings support previously demonstrated effects of cardiopulmonary exercise tests with comparable results at rest, maximum workload, and recovery. 11 Concerns have been raised that a reduction in central sympathetic activity by RDN could negatively influence cardiovascular response and exercise tolerance. 24 However, the improvements in the mean workload and mean exercise time indicate an improved exercise capacity after RDN.
Nonresponse to RDN, defined as office SBP reduction <10 mm Hg after 6 months, was observed in 14% (7) of the patients. This is consistent with previous studies showing nonresponse rates between 8% and 17%. 9, 25, 26 The causes of nonresponse are not completely understood. Several hypotheses such as inappropriate patient selection, presence of secondary hypertension, subordinate relevance of sympathetic activation, or ineffective RDN have been proposed. 26 Interestingly, nonresponders to office BP showed a mean BP reduction of 27 mm Hg at 100 W of exercise. This reduction in exercise BP was similar to the one observed in responders. At individual maximum workloads, 5 office nonresponders had an exercise BP reduction of ≥10 mm Hg. These data suggest that an improved BP response during exercise (eg, defined as a reduction of ≥10 mm Hg in SBP at the individual maximal threshold) may be considered as a criterion of response after RDN even in the absence of an adequate office SBP reduction. Ongoing studies (Symplicity HTN-3 [NCT01418261] ) and future investigations will help to answer the question whether nonresponders showing improvements in BP during exercise also experience clinical benefits from RDN.
Exercise HR is an independent predictor of cardiovascular mortality and morbidity 27 especially in patients with hypertension. 2 In addition to decreased BP, a reduction in HR at rest and during exercise and recovery was observed in patients with resistant hypertension after RDN. The HR reductions after RDN found herein are in line with the results obtained from cardiopulmonary exercise tests.
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The CI reflects the ratio of the HR reserve to the metabolic reserve during submaximal exercise and is adjusted for age, physical fitness, and functional capacity, thereby remaining unaffected by testing protocols.
14 Chronotropic incompetence is defined as failure to achieve <80% of the age-predicted maximal HR 28 and has been suggested to be related to alterations of the autonomic nervous system. 14 The concern that RDN could possibly induce CI might be mitigated by this investigation showing that CI remained unchanged, whereas the achieved workloads increased during exercise testing.
Limitations
The control group consisted of 10 patients. Therefore, smaller differences between the treatment group and the control group might not reach statistical significance. Because the study was focused on the BP changes after 6 months, the number of patients completing 12-month FU is lower compared with the other time points. Therefore, the group of patients with 12-month FU illustrates that the effects of RDN on BP are sustained for a longer time period. These findings are consistent with the final 3-year report of the Symplicity HTN-1 study. 29 Furthermore, patients after 12 months did not significantly differ from those who were analyzed at 6-month FU with respect to disease severity or comorbidities. Lifestyle and daily life activity was not systematically assessed. However, the body mass index remained unchanged, and no change in exercise capacity over time was observed in the control group, making a relevant bias unlikely. Measurement of BP during exercise is challenging and may cause recording of unreliable values, especially during high-intensity exercise. To address the latter limitation, experienced physicians performed BP measurements. After 6-month FU, in the RDN group drug treatment was reduced in 4 patients because of symptomatic hypotension with SBP <120 mm Hg and increased in 2 of the nonresponders. Even after exclusion of postprocedural medication changes, no significant differences were observed, making a relevant influence unlikely.
Perspectives
This study shows that RDN reduced BP and HR at rest, during physical exercise, and at recovery, improved CI, and improved exercise capacity measured by workload and exercise time, without adversely affecting the physiological response to exercise in patients with resistant hypertension. Our data suggest an improved BP response during exercise testing even in the absence of an adequate office SBP reduction (nonresponse). These effects were demonstrated in exercise stress tests that are easily applicable in clinical practice. • This prospective study investigated the effects of renal denervation on blood pressure, heart rate, and chronotropic index at rest, during exercise, and at recovery in 60 patients (renal denervation group=50, control group=10) with resistant hypertension using a standardized bicycle exercise test protocol.
• Improved blood pressure response during exercise testing may be considered as a criterion of response determination after renal denervation even in the absence of an adequate office systolic blood pressure reduction.
What Is Relevant?
• Exercise blood pressure and heart rate are associated with well-established cardiovascular risk factors and are correlated with morbidity and mortality.
Summary
The study shows that renal denervation reduces blood pressure and heart rate at rest, during physical exercise, and at recovery and results in improved chronotropic index and improved mean workload without adversely affecting the physiological response to exercise in patients with resistant hypertension. Table legends online supplement   Table S1 : Systolic blood pressure values at exercise and resting (RDN and control group) Values are mean ± SE. p values are baseline versus 6-month or 12-month follow-up.
